PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1983305
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1983305
U.S. Medical Foods Market is estimated to be valued at USD 9.2 Bn in 2026 and is expected to reach USD 13.19 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.30% | 2033 Value Projection: | USD 13.19 Bn |
A medical food is specifically formulated for patients, who require medical food as a major part of their dietary supplement during treatment. They are custom-made liquid solutions created with the sole purpose of curing persons suffering from various illnesses. Professionals provide the designed meal to people suffering from various illnesses. It is a specially prepared diet that provides patients with adequate nutrients.
Medical foods are available in different forms such as powders, liquids, and even gum. Moreover, medical foods are more commonly used to treat chronic conditions and diseases through long-term use in an outpatient setting. Manufacturers are developing products for new illness indications, fueling growth of the medical food market. Medical food is specifically tailored to meet the nutritional and metabolic demands of those suffering from a specific illness.
Medical foods are also used in the treatment of other gastrointestinal diseases such as diarrhea, constipation, gastroenteritis, peptic ulcer diseases, and colorectal cancer, which is expected to propel market growth over the forecast period. Moreover, the increasing geriatric population suffering from several chronic and neurogenic disorders such as dementia, stroke, multiple sclerosis, and difficulty in swallowing requires specific dietary management, which, in turn, is expected to drive the market growth over the forecast period. For instance in July 2019, Georgetown University entered into a collaboration with National Center for Complementary and Integrative Health (NCCIH), University of Maryland, a United States government agency which explores complementary and alternative medicine, initiated early phase 1 clinical trial to demonstrate the mechanisms of preventing antibiotic-associated diarrhea and the role of probiotics.
Key features of the study